Synopsis: In a recently issued final written decision, the Patent Trial and Appeal Board (the “Board”) found all challenged claims of U.S.

These reductions are comparable to those observed with tamoxifen, a commonly prescribed therapy, but were achieved at much lower doses of (Z)-endoxifen, offering improved tolerability. Both doses ...

Whether increasing the dose of tamoxifen would improve efficacy is not known, nor whether using another form of endocrine therapy such as ovarian suppression with or without an aromatase inhibitor ...

(Z)-endoxifen appears to deliver similar or even greater bone agonistic effects while resulting in little or no endometrial proliferative effects compared with standard treatments, like tamoxifen.

Tamoxifen treatment has been linked to an excess risk of nonalcoholic steatohepatitis, which is characterized by inflammation and fatty deposits in the liver. Bruno and colleagues have ...

These reductions are comparable to those observed with tamoxifen, a commonly prescribed therapy, but were achieved at much lower doses of (Z)-endoxifen, offering improved tolerability. Both doses ...

Detailed price information for Atossa Therapeutics Inc (ATOS-Q) from The Globe and Mail including charting and trades.